Literature DB >> 6980812

Demonstration of non-specific B-cell stimulation in patients with cirrhosis.

G Holdstock, W B Ershler, E L Krawitt.   

Abstract

Using a sensitive enzyme-linked immunosorbent assay technique to measure immunoglobulins produced by peripheral lymphocytes, patients with cirrhosis with, and without, hypergammaglobulinaemia were found to produce significantly more spontaneous IgG than controls (p less than 0.005). There was no difference in IgG production when pokeweed mitogen, a T-cell dependent B-cell mitogen, was added to the system. Contrary to our findings in a T-cell proliferative assay, there was no evidence of increased prostaglandin-producing suppressor cell activity in this system. To study the importance of B-cell stimulation in cirrhotic hyperglobulinaemia, normal mononuclear cells were exposed either to cirrhotic or to control sera before measuring spontaneous IgG production. Cells exposed to cirrhotic sera produced significantly more IgG than those exposed to the control sera (p less than 0.02). These findings suggest that non-specific B-cell activity occurs with patients in cirrhosis and it is argued that the severity of the hypergammaglobulinaemia in patients with cirrhosis is more likely to depend on the degree of non-specific B-cell stimulation than on the competence of the immunoregulatory system.

Entities:  

Mesh:

Substances:

Year:  1982        PMID: 6980812      PMCID: PMC1419764          DOI: 10.1136/gut.23.9.724

Source DB:  PubMed          Journal:  Gut        ISSN: 0017-5749            Impact factor:   23.059


  24 in total

1.  Alteration in suppressor cell activity in chronic active hepatitis.

Authors:  H J Hodgson; J R Wands; K J Isselbacher
Journal:  Proc Natl Acad Sci U S A       Date:  1978-03       Impact factor: 11.205

2.  Hyperglobulinaemia in liver disease.

Authors:  D R Triger; R Wright
Journal:  Lancet       Date:  1973-06-30       Impact factor: 79.321

3.  Antibodies to intestinal microbes in serum of patients with cirrhosis of the liver.

Authors:  M Bjorneboe; H Prytz; F Orskov
Journal:  Lancet       Date:  1972-01-08       Impact factor: 79.321

4.  Bacterial and dietary antibodies in liver disease.

Authors:  D R Triger; M H Alp; R Wright
Journal:  Lancet       Date:  1972-01-08       Impact factor: 79.321

5.  Immunoglobulins in chronic liver disease.

Authors:  T Feizi
Journal:  Gut       Date:  1968-04       Impact factor: 23.059

6.  Enzyme-linked immunosorbent assay (ELISA). Quantitative assay of immunoglobulin G.

Authors:  E Engvall; P Perlmann
Journal:  Immunochemistry       Date:  1971-09

7.  The T cell dependence of B cell differentiation induced by pokeweed mitogen.

Authors:  R G Keightley; M D Cooper; A R Lawton
Journal:  J Immunol       Date:  1976-11       Impact factor: 5.422

8.  Tetanus antitoxin production and gamma globulin levels in patients with cirrhosis of the liver.

Authors:  M Bjorneboe; K B Jensen; I Scheibel; A C Thomsen; M W Bentzon
Journal:  Acta Med Scand       Date:  1970-12

9.  Peripheral blood lymphocyte populations in chronic liver disease.

Authors:  H C Thomas; M Freni; J Sanchez-Tapias; D de Villiers; S Jain; S Sherlock
Journal:  Clin Exp Immunol       Date:  1976-11       Impact factor: 4.330

10.  Portal venous and systemic endotoxaemia in patients without liver disease and systemic endotoxaemia in patients with cirrhosis.

Authors:  H Prytz; J Holst-Christensen; B Korner; H Liehr
Journal:  Scand J Gastroenterol       Date:  1976       Impact factor: 2.423

View more
  10 in total

1.  Dysfunctional B-cell activation in cirrhosis resulting from hepatitis C infection associated with disappearance of CD27-positive B-cell population.

Authors:  Hiroyoshi Doi; Tara K Iyer; Erica Carpenter; Hong Li; Kyong-Mi Chang; Robert H Vonderheide; David E Kaplan
Journal:  Hepatology       Date:  2012-01-19       Impact factor: 17.425

2.  Immunoglobulin production by peripheral blood mononuclear cells in patients with alcoholic liver disease.

Authors:  M A Rodriguez; J D Montano; R C Williams
Journal:  Clin Exp Immunol       Date:  1984-02       Impact factor: 4.330

3.  Polyclonal B cell activation in alcoholic patients with no evidence of liver dysfunction.

Authors:  P A Drew; P M Clifton; J T LaBrooy; D J Shearman
Journal:  Clin Exp Immunol       Date:  1984-08       Impact factor: 4.330

4.  In vitro immunoglobulin synthesis by human intestinal lamina propria lymphocytes.

Authors:  P A Drew; J T La Brooy; D J Shearman
Journal:  Gut       Date:  1984-06       Impact factor: 23.059

5.  The significance of C-reactive protein to albumin ratio in patients with decompensated cirrhosis.

Authors:  Theodora Oikonomou; Ioannis Goulis; Stefania Kiapidou; Nikoletta Tagkou; Evangelos Akriviadis; George Papatheodoridis; Evangelos Cholongitas
Journal:  Ann Gastroenterol       Date:  2020-09-16

6.  Hyperglobulinaemia in chronic liver disease: relationships between in vitro immunoglobulin synthesis, short lived suppressor cell activity and serum immunoglobulin levels.

Authors:  P B Rong; J Kalsi; H J Hodgson
Journal:  Clin Exp Immunol       Date:  1984-03       Impact factor: 4.330

7.  Interleukin-2 activity in chronic active liver diseases: response by T cells and in the autologous mixed lymphocyte reaction.

Authors:  K Yoshioka; S Kakumu; H Murakami; K Fukui
Journal:  Clin Exp Immunol       Date:  1984-06       Impact factor: 4.330

8.  Suppression of immunoglobulin synthesis by activated B cells in chronic active liver diseases and primary biliary cirrhosis.

Authors:  S Kakumu; K Fukui; K Yoshioka; H Murakami
Journal:  Gastroenterol Jpn       Date:  1986-02

9.  Endotoxemia contributes to CD27+ memory B-cell apoptosis via enhanced sensitivity to Fas ligation in patients with Cirrhosis.

Authors:  Li-Yuan Chang; Yonghai Li; David E Kaplan
Journal:  Sci Rep       Date:  2016-11-18       Impact factor: 4.379

Review 10.  The Contribution of Liver Sinusoidal Endothelial Cells to Clearance of Therapeutic Antibody.

Authors:  Bethany H James; Pantelitsa Papakyriacou; Matthew J Gardener; Louise Gliddon; Christopher J Weston; Patricia F Lalor
Journal:  Front Physiol       Date:  2022-01-14       Impact factor: 4.566

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.